study
clinical efficacy
incidence
torsades de pointes
presumable risk factors
torsades
de pointes
patients
treated with
l-sotalol
sustained
ventricular tachyarrhythmias
consecutive
patients
coronary artery disease
dilated cardiomyopathy
inducible
ventricular tachycardia
ventricular fibrillation
oral d
l-sotalol
induction
ventricular tachyarrhythmia
oral
loading
l-sotalol
continuous electrocardiographic (
ECG
monitoring
patients
l-sotalol
induction
ventricular tachycardia
ventricular fibrillation
discharged
drug
followed up
outpatient
months
Induction
ventricular tachyarrhythmia
oral
l-sotalol
patients
ventricular tachyarrhythmia
inducible
patients
patients
l-sotalol
patients
torsades de pointes
oral treatment
l-sotalol
ECG
sinus-cycle length
SCL
QT
QTc interval
U wave
clinical parameters
patients
risk
torsades de pointes
oral dose
l-sotalol
patients
torsades de pointes
Risk factors
associated with
development
torsades de pointes
appearance
U wave
female
gender
dose-corrected changes
SCL
QT interval
QTc interval
follow-up
patients
nonfatal ventricular tachycardia recurrence
patients
died
female
patient
stable cardiac disease
recurrent
torsades
de pointes
years
treatment
l-sotalol
Torsades de pointes
treatment
low
doses
oral d
l-sotalol
surface
ECG
cycle length
QT
QTc
dose
oral
l-sotalol
subgroup
patients
increased
risk
torsades de pointes
ECG
parameters
application
l-sotalol
patients
increased risk
torsades de pointes
Recurrence
rates
ventricular tachyarrhythmias
suppression
arrhythmia
programmed stimulation
programmed electrical stimulation
l-sotalol
prognostic value
